These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 12435172

  • 41. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 42. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Jan; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 43. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
    Doshi S, Chow A, Pérez Ruixo JJ.
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
    [Abstract] [Full Text] [Related]

  • 44. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.
    Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
    [Abstract] [Full Text] [Related]

  • 45. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R.
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [Abstract] [Full Text] [Related]

  • 46. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group.
    J Natl Cancer Inst; 2002 Aug 21; 94(16):1211-20. PubMed ID: 12189224
    [Abstract] [Full Text] [Related]

  • 47. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep 21; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG, Natale JJ.
    Pharmacotherapy; 2007 Mar 21; 27(3):434-46. PubMed ID: 17316154
    [Abstract] [Full Text] [Related]

  • 50. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 21; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.
    Curr Med Res Opin; 2012 Jul 21; 28(7):1089-99. PubMed ID: 22642866
    [Abstract] [Full Text] [Related]

  • 53. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ.
    Pharmacotherapy; 2007 May 21; 27(5):734-44. PubMed ID: 17461709
    [Abstract] [Full Text] [Related]

  • 54. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep 21; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 55. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J.
    Oncol Nurs Forum; 2005 Jan 19; 32(1):81-91. PubMed ID: 15660146
    [Abstract] [Full Text] [Related]

  • 56. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
    Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
    Curr Med Res Opin; 2011 Feb 19; 27(2):355-63. PubMed ID: 21166611
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K.
    J Am Coll Cardiol; 2007 Feb 20; 49(7):753-62. PubMed ID: 17306703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.